Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543672 · ClinicalTrials.gov registry record · Phase 1
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
A Phase 1 study of Lung Cancer and Metastatic Lung Cancer, sponsored by The Netherlands Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 5
- Study locations
NCT01543672 is a Phase 1 study of Lung Cancer and Metastatic Lung Cancer that has completed, run by The Netherlands Cancer Institute. The registered enrollment target is 62 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01543672, a Phase 1 study of Lung Cancer and Metastatic Lung Cancer, has completed, sponsored by The Netherlands Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 5
- Study locations
Study Summary
Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation study.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiotherapy (SBRT)
Study Locations (5)
Michigan
- Beaumont Hospital, Royal Oak - Royal Oak
Pennsylvania
- Thomas Jefferson University/ Kimmel Cancer Center - Philadelphia
Ontario
- Prinses Margaret Hospital - Toronto
Bavaria
- Universitätsklinikum Würzburg - Würzburg
Other
- NKI-AVL - Amsterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2011-11-22 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543672
The ClinicalTrials.gov registry entry for NCT01543672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The listed sponsor is The Netherlands Cancer Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Body Radiotherapy (SBRT) is the first listed.
NCT01543672 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Michigan, Pennsylvania, Ontario.
Frequently Asked Questions
What is clinical trial NCT01543672 about?
NCT01543672 is a clinical study titled "Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously". Treatment of larger tumor volumes or ≥ 2 lung metastases simultaneously in lung cancer patient using Stereotactic Body Radiation Therapy (SBRT) in a mean-lung dose escalation study.
What is the current status of trial NCT01543672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2011-11-22. Estimated completion is 2017-10-31.
What conditions does trial NCT01543672 study?
This clinical trial studies the following conditions: Lung Cancer, Metastatic Lung Cancer.
What interventions are being tested in trial NCT01543672?
The interventions under investigation include: Stereotactic Body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01543672?
This trial is sponsored by The Netherlands Cancer Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01543672 being conducted?
This trial has 5 study locations across Michigan, Pennsylvania, Ontario, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.